ArticleMicrobiome2022
Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis.
Article in Microbiome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 70 citations in OpenAlex.
- Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.mSystems · 2026Article
- Safety Assessment on Probiotic Mixture "Prohep" and Longitudinal Evaluation on its Gut Microbial Modulation Ability in Mice.Probiotics and antimicrobial proteins · 2026Article
- Linking the microbiome to the complement system in geographic atrophy.NPJ genomic medicine · 2026Article
- Acute high-intensity exercise alters gut microbiota composition and energy metabolism in different strains of mice.Frontiers in microbiology · 2026Article
- Effects of D-Glucosamine on the Growth of Human Gut-Dominant MicrobiotaJournal of applied glycoscience · 2026Article
- Evidence for dysbiosis in the gut microbiome of patients with systemic mastocytosis.The journal of allergy and clinical immunology. Global · 2026Article
- Modulation of gut microbiota and intestinal barrier by lotus seed, jujube, and longan aril in senna leaf-induced diarrhea in mice.Frontiers in microbiology · 2026Article
- Article
- Unraveling multiple sclerosis: a hidden interaction between intestinal microbiota and host lipid metabolism.Gut microbes · 2025Review
- The Use of Ampicillin-Medicated Diet to Treat Segmented Filamentous Bacteria in a Mouse (Mus musculus) Colony.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Dysregulation of gut microbiota stimulates NETs-driven HCC intrahepatic metastasis: therapeutic implications of healthy faecal microbiota transplantation.Gut microbes · 2025Article
- Redefining multiple sclerosis therapy through microbial immunomodulation and epigenetic control.Journal of translational autoimmunity · 2025Review
- Microbiome and metabolome changes in laying hens induced by dietary epsilon-polylysine.Poultry science · 2025Article
- Role of the gut-brain axis in neurological diseases: Molecular connections and therapeutic implications (Review).International journal of molecular medicine · 2025Review
- Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2025Review
- Review
- Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Landscapes of gut microbiome and blood metabolomic signatures in relapsing remitting multiple sclerosis.Science China. Life sciences · 2025Article
- Gut microbiota in multiple sclerosis and animal models.The FEBS journal · 2025Review
- A comprehensive assessment of immunomodulatory potentials of Korean antler velvet extract in mouse and neurodegenerativeJournal of animal science and technology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe gut microbiome plays an important role in autoimmunity including multiple sclerosis and its mouse model called experimental autoimmune encephalomyelitis (EAE). Prior studies have demonstrated that the multiple sclerosis gut microbiota can contribute to disease, hence making it a potential therapeutic target. In addition, antibiotic treatment has been shown to ameliorate disease in the EAE mouse model of multiple sclerosis. Yet, to this date, the mechanisms mediating these antibiotic effects are not understood. Furthermore, there is no consensus on the gut-derived bacterial strains that drive neuroinflammation in multiple sclerosis.
resultsHere, we characterized the gut microbiome of untreated and vancomycin-treated EAE mice over time to identify bacteria with neuroimmunomodulatory potential. We observed alterations in the gut microbiota composition following EAE induction. We found that vancomycin treatment ameliorates EAE, and that this protective effect is mediated via the microbiota. Notably, we observed increased abundance of bacteria known to be strong inducers of regulatory T cells, including members of Clostridium clusters XIVa and XVIII in vancomycin-treated mice during the presymptomatic phase of EAE, as well as at disease peak. We identified 50 bacterial taxa that correlate with EAE severity. Interestingly, several of these taxa exist in the human gut, and some of them have been implicated in multiple sclerosis including Anaerotruncus colihominis, a butyrate producer, which had a positive correlation with disease severity. We found that Anaerotruncus colihominis ameliorates EAE, and this is associated with induction of RORγt
conclusionsWe identified vancomycin as a potent modulator of the gut-brain axis by promoting the proliferation of bacterial species that induce regulatory T cells. In addition, our findings reveal 50 gut commensals as regulator of the gut-brain axis that can be used to further characterize pathogenic and beneficial host-microbiota interactions in multiple sclerosis patients. Our findings suggest that elevated Anaerotruncus colihominis in multiple sclerosis patients may represent a protective mechanism associated with recovery from the disease. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.